Membership Overview
Browsing articles in "Addiction/Reward"

 

Highlights from the 2017 APA Annual Meeting
June 8, 2017   

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.
 Continue reading
Marijuana Use in Pregnant Women Has Increased
January 13, 2017   

In a recent observational study, the prevalence of marijuana use in pregnant versus nonpregnant women was examined...
 Continue reading (Members only)
Increase in Opioid-Related Deaths Not Driven By Prescription Painkillers
January 12, 2017   

Opioid abuse remains an epidemic in the United States, with over 50,000 deaths associated with drug overdose, and 63% of those attributed to opioids...
 Continue reading (Members only)
FDA Update: Boxed Warnings in Varenicline and Bupropion Labels to Be Removed
December 19, 2016   

The results of a large clinical trial required by the FDA have shown that the risk of mental health side effects with the smoking cessation agents Chantix (varenicline) and Zyban (bupropion) is lower than previously thought...
 Continue reading (Members only)
FDA Approves Trials for MDMA as Treatment for PTSD
December 14, 2016   

As many as 24.5% of Iraq and Afghanistan veterans may suffer with posttraumatic stress disorder (PTSD), a disorder characterized by re-experiencing, avoidance, arousal, and changes to mood and cognition. Available pharmacological treatments approved for treating PTSD (sertraline and paroxetine) have very limited efficacy...
 Continue reading
SAMHSA Report: Results from the 2015 National Survey on Drug Use and Health
October 5, 2016   

In 2015, the National Survey on Drug Use and Health (NSDUH) was administered to people aged 12 and older in the United States, to collect data on indicators of substance use and mental health in this population...
 Continue reading (Members only)
FDA Alert: Medication and Medical Device Approvals
September 12, 2016   

The US FDA has approved the marketing of computerized cognitive tests to assess for possible concussions, granted tentative approval for Trokendi XR for migraine prevention, and approved abuse-deterrent Troxyca ER for severe pain management.
 Continue reading (Members only)
Does Transcranial Magnetic Stimulation Modulate Food Cravings?
August 29, 2016   

A recent meta-analysis evaluated whether transcranial magnetic stimulation (TMS) to the dorsolateral prefrontal cortex (dlPFC) modulates food cravings and consumption in laboratory and therapeutic contexts. Nine studies (N=189; mean age=26.7; female=89.9%; mean BMI=24.3 kg/m2) met criteria for examining the effects of TMS to the dlPFC on food cravings...
 Continue reading (Members only)
FDA Approvals: Iloperidone, Buprenorphine Implant, and Insomnia Device
June 21, 2016   

New FDA approvals include iloperidone for maintenance treatment of schizophrenia, a buprenorphine implant for treatment of opioid dependence, and a prescription device for insomnia.
 Continue reading (Members only)
No Increase in Neuropsychiatric Adverse Events in Large Controlled Trial of Smoking Cessation Treatments
May 1, 2016   

In a large multinational study requested by the FDA, Anthenelli et at. examined the neuropsychiatric safety of the smoking cessation medications bupropion and varenicline. The double-blind, triple-dummy, placebo-controlled and active-controlled study enrolled over 8,000 participants from 16 countries. All participants smoke on average more than half a pack...
 Continue reading (Members only)
123
Top of Page